ORCHPHARMA: BOARD APPROVES FUND RAISE OF UP TO ₹600 CR

ORCHPHARMA: BOARD APPROVES FUND RAISE OF UP TO ₹600 CR

• Board approved an enabling resolution to explore raising up to ₹600 Cr in the best interest of the company • Fund raise may be through equity shares or other eligible securities/instruments, including fully or partly convertible debentures • Proposed routes include QIP, private placement, public issue of equity and/or debt, preferential issue, or any combination thereof • Fund raise remains subject to statutory and regulatory approvals, including shareholder approval wherever applicable • Type of issuance, number of securities and final amount have not been decided as of now Impact: Positive — The enabling approval provides Orchid Pharma with flexibility to raise up to ₹600 Cr for future growth and funding requirements. However, the actual impact will depend on the final structure, pricing and potential dilution.